Table I.
Clinicopathological characteristics of healthy control individuals and patients with pSS.
| Clinicopathological characteristic | Patients with pSS | Healthy control patients | P-value |
|---|---|---|---|
| Cases, n | 95 | 68 | |
| Sex, Female | 95 (100%) | 68 (100%) | |
| Age, yearsa | 48.82±1.33 | 47.31±1.425 | 0.4472 |
| Disease duration (years)a | 1.54±0.221 | 0 | NA |
| ESSDAIc | 4 (0–7) | 0 (0–2) | <0.001 |
| Number of cariesc | 4 (1–8) | 0 | NA |
| Autoantibody positivity: | |||
| Anti-SSA and/or anti-SSBb | 95 (100) | 0 (0) | NA |
| Rheumatoid factorb | <0.001 | ||
| ≤20 | 31 (33%) | 68 (100%) | |
| ≥20 | 64 (67%) | 0 (0%) |
a
Mean ± standard error of the mean, analyzed by independent samples t-test;
b
number (percentage), analyzed by χ2 test;
c
Median (interquartile range), analyzed by the Mann-Whitney U test. C3, complement 3; C4, complement 4; ESR, erythrocyte sedimentation rate; ESSDAI, EULAR primary Sjögren's syndrome disease activity; ESSPRI, EULAR primary Sjögren's syndrome patient-reported indexes; NA, not applicable; pSS, primary Sjögren's syndrome.